An interventional study of intelligent robotic-assisted training and repetitive facilitative exercise in Stroke, sponsored by Nanjing Mingzhou Rehabilitation Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-03-05.
Sponsored by Nanjing Mingzhou Rehabilitation Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.
Among the 613 studies in Stroke with a site in China, this one is the 292nd largest by enrollment of the 432 interventional ones that give a count, is one of 71 that started in 2024, is one of 264 with no phase, and was the 416th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in China
Ages 18–80 · Healthy volunteers
Qingdao Central Hospital · Sites in China
Ages 18–75
Beijing Pins Medical Co., Ltd · Sites in China
Ages 18–75
Capital Medical University · Sites in China
Ages 18–80
Capital Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
613 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 47 · Phase 3 72 · Phase 4 42
First in 2000; this study’s year is marked. 71 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 169 across the 432 interventional studies, 611 across the 180 observational. Of the 211 that completed or were terminated, 31 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 613 have an industry lead sponsor. The 10 most frequent:
Nanjing Mingzhou Rehabilitation Hospital is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Nanjing Mingzhou Rehabilitation Hospital has 3 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
68 of the studies in Stroke with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05976152Phase 3Fudan UniversityEffect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER) | 2026-12 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
| NCT07002476Phase 3Shanghai East HospitalEarly Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion | 2027-03-01 |
| NCT07603102Nanjing Mingzhou Rehabilitation HospitalMindfulness With Dual-Task Training in Post-Stroke Mild Cognitive Impairment | 2026-11 |
Add all 68 to your calendar (.ics) → With an account.
Among the 613 studies in Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if intelligent rehabilitation robot training system combined with repetitive facilitative exercise (RFE) work to treat stroke in adults. The main questions it aims to answer are:
Does drug intelligent rehabilitation robot training system combined with RFE improve the upper limb motor function of participants? Can the combination of intelligent rehabilitation robot training system and RFE achieve better effects?
Researchers will compare 3 groups (RFE, intelligent rehabilitation robot training system under RFE, and conventional therapy) to see if intelligent rehabilitation robot training system and RFE works to treat stroke.
Participants will:
Receive treatment for 4 weeks Receive scale and instrument testing before and after treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Intelligent robotic-assisted training (IRAT) group received a 30 minute RFE intervention and a 30 minute IRAT intervention.
Device: intelligent robotic-assisted training · Other: repetitive facilitative exercise
The Repetitive facilitative exercise (RFE) group received a 60 minute RFE intervention.
Other: repetitive facilitative exercise
The Conventional therapy (CT) group received a 60 minute conventional rehabilitation intervention.
Other: conventional therapy
Using an intelligent robotic-assisted training (IRAT) system to simulate a real work environment, providing functional oriented treatment for stroke patients and improving upper limb motor function. The instrument used is the Burt upper limb robot training system produced by Estun Medical Co., Ltd.
Repetitive facilitative exercise (RFE) is a new technology that combines multiple sensory stimuli and achieves facilitation and reinforcement of the reconstruction of paralyzed neural pathways through repeated and extensive directional exercise.
Basic training, including passive joint movement and activities of daily living exercise.
Fugl-Meyer Assessment for Upper Extremity (FMA-UE)
The FMA-UE consists of 33 items across nine components, including reflex action, synergy, and coordination, with a maximum score of 66 points. Each items is scored from 0 (no ability) to 2 (full ability), with higher scores indicating better upper limb motor function.
Time frame: From enrollment to the end of treatment at 4 weeks
Active Participation Proportion
Active Participation Proportion (APP) is measured using the benchmark evaluation system within the intelligent rehabilitation robot training system. The robotic arm's mechanical sensor continuously detects the force exerted by the patient during the test game and quantifies APP as the ratio of the patient's applied force to the total force required to complete the task (%). A higher APP indicates greater voluntary effort in movement execution. Since the test game difficulty is fixed, APP increases as the patient's motor ability improves.
Time frame: From enrollment to the end of treatment at 4 weeks
Trajectory Deviation
Trajectory Deviation (TD) is assessed by comparing the actual motion trajectory with a predefined reference trajectory using the intelligent rehabilitation robot training system. TD is calculated as the mean Euclidean distance (in mm) between discrete points along the actual movement path and the nearest corresponding points on the reference trajectory. This metric provides a measure of point-specific accuracy and precision in following the ideal movement path, with smaller TD values indicating better trajectory control.
Time frame: From enrollment to the end of treatment at 4 weeks
Trajectory Tracking Error
Description: Trajectory Tracking Error (TTE) quantifies the cumulative deviation between the actual movement path and the predefined reference trajectory. It is computed as the sum of absolute differences in trajectory length between the two paths (in mm). TTE reflects overall movement efficiency and smoothness, capturing the patient's ability to maintain an optimal movement path throughout the task. A lower TTE indicates better movement planning and motor control.
Time frame: From enrollment to the end of treatment at 4 weeks
| Milestone | IRAT Group | RFE Group | CT Group |
|---|---|---|---|
| Started | 27 | 27 | 27 |
| Completed | 25 | 26 | 25 |
| Not completed | 2 | 1 | 2 |
The FMA-UE consists of 33 items across nine components, including reflex action, synergy, and coordination, with a maximum score of 66 points. Each items is scored from 0 (no ability) to 2 (full ability), with higher scores indicating better upper limb motor function.
| score on a scale | IRAT Group | RFE Group | CT Group |
|---|---|---|---|
| baseline | 34.4 ± 3.5 | 34.9 ± 3.8 | 35.8 ± 3.9 |
| 4 weeks | 49.0 ± 3.3 | 44.2 ± 3.6 | 38.8 ± 3.8 |
Active Participation Proportion (APP) is measured using the benchmark evaluation system within the intelligent rehabilitation robot training system. The robotic arm's mechanical sensor continuously detects the force exerted by the patient during the test game and quantifies APP as the ratio of the patient's applied force to the total force required to complete the task (%). A higher APP indicates greater voluntary effort in movement execution. Since the test game difficulty is fixed, APP increases as the patient's motor ability improves.
| percentage of active participation | IRAT Group | RFE Group | CT Group |
|---|---|---|---|
| baseline | 61.7 ± 4.8 | 104.0 ± 7.9 | 60.8 ± 6.1 |
| 4 weeks | 80.4 ± 5.3 | 61.6 ± 2.8 | 60.9 ± 2.6 |
Trajectory Deviation (TD) is assessed by comparing the actual motion trajectory with a predefined reference trajectory using the intelligent rehabilitation robot training system. TD is calculated as the mean Euclidean distance (in mm) between discrete points along the actual movement path and the nearest corresponding points on the reference trajectory. This metric provides a measure of point-specific accuracy and precision in following the ideal movement path, with smaller TD values indicating better trajectory control.
| millimeter | IRAT Group | RFE Group | CT Group |
|---|---|---|---|
| baseline | 104.0 ± 7.9 | 100.7 ± 8.9 | 99.5 ± 8.3 |
| 4 weeks | 65.7 ± 8.0 | 98.1 ± 5.7 | 95.7 ± 4.7 |
Description: Trajectory Tracking Error (TTE) quantifies the cumulative deviation between the actual movement path and the predefined reference trajectory. It is computed as the sum of absolute differences in trajectory length between the two paths (in mm). TTE reflects overall movement efficiency and smoothness, capturing the patient's ability to maintain an optimal movement path throughout the task. A lower TTE indicates better movement planning and motor control.
| millimeter | IRAT Group | RFE Group | CT Group |
|---|---|---|---|
| baseline | 60.8 ± 6.1 | 60.5 ± 6.0 | 61.6 ± 5.8 |
| 4 weeks | 36.8 ± 6.6 | 58.0 ± 2.8 | 59.1 ± 2.8 |
Collected over All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IRAT Group | — | — | — |
| RFE Group | — | — | — |
| CT Group | — | — | — |
| Age, Continuous(years) | IRAT Group | RFE Group | CT Group | Total |
|---|---|---|---|---|
| Mean | 51.6 ± 12.3 | 46.8 ± 11.7 | 50.3 ± 14.0 | 49.5 ± 12.7 |
| Sex: Female, Male(Participants) | IRAT Group | RFE Group | CT Group | Total |
|---|---|---|---|---|
| Female | 10 | 10 | 9 | 29 |
| Male | 15 | 16 | 16 | 47 |
| Race (NIH/OMB)(Participants) | IRAT Group | RFE Group | CT Group | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 25 | 26 | 25 | 76 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | IRAT Group | RFE Group | CT Group | Total |
|---|---|---|---|---|
| China | 25 | 26 | 25 | 76 |
| Affected side, left/right(participants) | IRAT Group | RFE Group | CT Group | Total |
|---|---|---|---|---|
| left | 12 | 12 | 14 | 38 |
| right | 13 | 14 | 11 | 38 |
| Time from stroke, days(days) | IRAT Group | RFE Group | CT Group | Total |
|---|---|---|---|---|
| Mean | 256.2 ± 60.1 | 254.7 ± 46.0 | 270.1 ± 55.8 | 260.3 ± 53.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2024 to primary completion in Aug 2024, 2 months.
Results were first posted in Mar 2025, 6 months after primary completion.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 2 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanjing Mingzhou Rehabilitation Hospital